BioRestorative Therapies (BRTX) Current Leases (2019 - 2024)
BioRestorative Therapies' (BRTX) quarterly Current Leases came in at $42414.0 in Q3 2024, down 72.87% YoY from $156310.0 in Q4 2023, and down 49.25% on a QoQ basis from $83580.0 in Q2 2024.
BioRestorative Therapies (BRTX) Current Leases (2019 - 2024) Analysis & Trends
BioRestorative Therapies (BRTX) has 6 years of Current Leases data on file, last reported at $42414.0 in Q3 2024.
- Quarterly Current Leases fell 72.87% year-over-year to $42414.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $42414.0 (down 72.87% YoY) and the FY2023 annual result came in at $162317.0, up 16.5% from the prior year.
- Current Leases eased to $42414.0 in Q3 2024, from $83580.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $162317.0 in Q4 2023 to a low of $42414.0 in Q3 2024.
- A 5-year average of $119796.8 and a median of $123536.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2020 — Current Leases soared 85.31% — and 2024, when it plunged 72.87%.
- Tracing BRTX's Current Leases over 5 years: stood at $158371.0 in 2020, then dropped by 24.83% to $119055.0 in 2021, then climbed by 17.03% to $139328.0 in 2022, then climbed by 16.5% to $162317.0 in 2023, then sank by 73.87% to $42414.0 in 2024.
- The last three Current Leases figures came in at $42414.0 (Q3 2024), $83580.0 (Q2 2024), and $123536.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 42,414.00 |
| Jun 30, 2024 | 83,580.00 |
| Mar 31, 2024 | 123,536.00 |
| Dec 31, 2023 | 162,317.00 |
| Sep 30, 2023 | 156,310.00 |
| Jun 30, 2023 | 150,480.00 |
| Mar 31, 2023 | 144,821.00 |
| Dec 31, 2022 | 139,328.00 |
| Sep 30, 2022 | 134,031.00 |
| Jun 30, 2022 | 128,899.00 |
| Mar 31, 2022 | 123,899.00 |
| Dec 31, 2021 | 119,055.00 |
| Sep 30, 2021 | 114,387.00 |
| Jun 30, 2021 | 109,856.00 |
| Mar 31, 2021 | 105,459.00 |
| Dec 31, 2020 | 158,371.00 |
| Sep 30, 2020 | 97,081.00 |
| Jun 30, 2020 | 93,093.00 |
| Mar 31, 2020 | 89,222.00 |
| Dec 31, 2019 | 85,465.00 |